Impax Receives 483s at Separate Manufacturing Plants

Drug GMP Report
Impax received two Form 483s less than a week apart for poor inspections of two manufacturing facilities, igniting fresh doubts on the company’s plan to win approval of its Parkinson’s drug Rytary.

To View This Article:


Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $157.00